Using a tool to personalize antibiotic dosing in the ICU
Part of Infections clinical trials.
This study tests a computer tool that helps doctors give the right dose of strong antibiotics to ICU patients. It is for adults who have recently started one of two specific antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are admitted to the intensive care unit (ICU).
- You are 18 years of age or older.
- You have started taking either piperacillin-tazobactam or meropenem (strong antibiotics) within the last 48 hours.
- You are not pregnant or breastfeeding.
- Your medical team does not expect the end of life within the next 48 hours.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized dosing approach for certain antibiotics (amoxicillin-clavulanic acid, piperacillin-tazobactam, and meropenem) in hospitalized children with serious infections. The goal is to adjust the dose based on blood tests to make sure each child gets the right amount of medicine.
This study looks at whether giving common antibiotics in certain dose schedules (either through a drip over time or continuously) is done in a way that fits pediatric intensive care needs. It may help improve antibiotic treatment for children who are very sick and need antibiotics.
This trial checks if giving higher doses of beta-lactam antibiotics (a type of strong antibiotic) right from the start helps people in the ICU with septic shock. It aims to find the best dose to fight the infection quickly.
This trial tests a new device that measures antibiotic levels in blood quickly at the bedside, so doctors can adjust your dose to make sure it's effective. It may help ICU patients on beta-lactam antibiotics get the right amount.
This study validates a prediction tool designed to identify which ICU patients are at risk of developing multidrug-resistant gram-negative bacteria (a serious infection resistant to many antibiotics). The tool may help doctors start appropriate treatment earlier and improve patient outcomes.
This trial tests whether using a blood test called 'PCT' can help doctors decide when to start or stop antibiotics in critically ill adult patients in the EICU. The goal is to reduce unnecessary antibiotic use while still effectively treating bacterial infections.
Hear when a new Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.